Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group

High‐level MYCN amplification (MNA) is associated with poor outcome and unfavorable clinical and biological features in patients with neuroblastoma. To the authors' knowledge, less is known regarding these associations in patients with low‐level MYCN copy number increases.

[1]  A. Naranjo,et al.  A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study. , 2016 .

[2]  John T. Powers,et al.  Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma , 2016, Nature.

[3]  A. Naranjo,et al.  Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Children’s Oncology Group (COG) study. , 2016 .

[4]  P. Ambros,et al.  The genetic tumor background is an important determinant for heterogeneous MYCN‐amplified neuroblastoma , 2016, International journal of cancer.

[5]  P. Ambros,et al.  Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors , 2016, Oncogene.

[6]  M. Fischer,et al.  Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project , 2016, Cancer.

[7]  J. Neuhaus,et al.  Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Look,et al.  Age-Dependent Prognostic Effect by Mitosis-Karyorrhexis Index in Neuroblastoma: A Report from the Children's Oncology Group , 2014, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[9]  J. Maris,et al.  Children's Oncology Group's 2013 blueprint for research: Neuroblastoma , 2013, Pediatric blood & cancer.

[10]  L. Gong,et al.  Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients , 2013, Diagnostic Pathology.

[11]  J. Khan,et al.  Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project , 2012, British Journal of Cancer.

[12]  I. Yaniv,et al.  2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics. , 2010, The American journal of pathology.

[13]  J. Maris,et al.  Lestaurtinib Enhances the Antitumor Efficacy of Chemotherapy in Murine Xenograft Models of Neuroblastoma , 2010, Clinical Cancer Research.

[14]  H. Caron,et al.  Neuroblastoma: biology, prognosis, and treatment. , 2010, Hematology/oncology clinics of North America.

[15]  J Khan,et al.  International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee , 2009, British Journal of Cancer.

[16]  Barbara Hero,et al.  The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Cole,et al.  Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression , 2007, Genes, chromosomes & cancer.

[18]  E. Connolly,et al.  Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma. , 2006, Neurosurgery.

[19]  Hiroyuki Shimada,et al.  Chromosome 1p and 11q deletions and outcome in neuroblastoma. , 2005, The New England journal of medicine.

[20]  K K Matthay,et al.  Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  F. Berthold,et al.  MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification. , 2004, European journal of cancer.

[22]  F. Speleman,et al.  Quality assessment of genetic markers used for therapy stratification. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  F. Speleman,et al.  Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification , 2001, International journal of cancer.

[24]  D. Stram,et al.  Comprehensive analysis of chromosome 1p deletions in neuroblastoma. , 2001, Medical and pediatric oncology.

[25]  J. Lunec,et al.  Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group. , 2001, Medical and pediatric oncology.

[26]  K K Matthay,et al.  The International Neuroblastoma Pathology Classification (the Shimada system) , 1999, Cancer.

[27]  A. Look,et al.  Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. , 1997, Journal of the National Cancer Institute.

[28]  F. Berthold,et al.  Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.

[29]  A T Look,et al.  Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  N C Dracopoli,et al.  Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[31]  P. Waber,et al.  N-myc oncogene RNA expression in neuroblastoma. , 1988, Journal of the National Cancer Institute.

[32]  P. Brandtzaeg,et al.  Prognostic factors in Neuroblastoma. Clinical, histopathologic, and immunohistochemical features and DNA ploidy in relation to prognosis , 1988, Cancer.

[33]  H. Sather,et al.  Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. , 1985, The New England journal of medicine.

[34]  H. Varmus,et al.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.

[35]  P. Armitage.  Tests for Linear Trends in Proportions and Frequencies , 1955 .